Major Strides in HER2 Blockade for Metastatic Breast Cancer

被引：10
作者：
Sharma, Priyanka [1 ]
机构：
[1] Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 382卷 / 07期
关键词：
TRASTUZUMAB; PERTUZUMAB; DOCETAXEL; SURVIVAL;
D O I：
10.1056/NEJMe1916310
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Breast cancer that is characterized by amplification or overexpression of human epidermal growth factor receptor 2 (HER2) accounts for 15 to 20% of all forms of the disease. The advent of HER2-targeted drugs, such as trastuzumab, pertuzumab, lapatinib, and the antibody-drug conjugate trastuzumab emtansine, has revolutionized the treatment of both early-stage and metastatic HER2-positive breast cancer.(1-4) The increasing availability of HER2-targeted agents has led to improved outcomes for patients with HER2-positive metastatic breast cancer, as reported in a study in which overall survival rose from a median of 38.7 months to 51.1 months from 2008 through 2012.(5) The standard first-line . . .
引用
收藏
页码：669 / 671
页数：3
相关论文
共 50 条
  • [21] Dual HER2 blockade in adjuvant and neoadjuvant treatment of HER2-positive breast cancer: the role of pertuzumab
    Duchnowska, Renata
    ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 (01): : 43 - 47
  • [22] Dual HER2 Blockade in Neoadjuvant Treatment of HER2+Breast Cancer: A Meta-Analysis and Review
    Wang, Chaokun
    Chen, Jing
    Xu, Xiangyun
    Hu, Xiaochen
    Kong, Dejiu
    Liang, Gaofeng
    Wang, Xinshuai
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2020, 19
  • [23] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Elisa Van Raemdonck
    G. Floris
    P. Berteloot
    A. Laenen
    I. Vergote
    H. Wildiers
    K. Punie
    P. Neven
    Breast Cancer Research and Treatment, 2021, 185 : 183 - 194
  • [24] Issues and controversies in the treatment of HER2 positive metastatic breast cancer
    Amar, Surabhi
    Moreno-Aspitia, Alvaro
    Perez, Edith A.
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (01) : 1 - 7
  • [25] Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene
    Harbeck, Nadia
    Pegram, Mark D.
    Rueschoff, Josef
    Moebus, Volker
    BREAST CARE, 2010, 5 : 3 - 7
  • [26] Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
    Adam-Artigues, Anna
    Arenas, Enrique J.
    Martinez-Sabadell, Alex
    Braso-Maristany, Fara
    Cervera, Raimundo
    Tormo, Eduardo
    Hernando, Cristina
    Teresa Martinez, Maria
    Carbonell-Asins, Juan
    Simon, Soraya
    Poveda, Jesus
    Moragon, Santiago
    Zazo, Sandra
    Martinez, Debora
    Rovira, Ana
    Burgues, Octavio
    Rojo, Federico
    Albanell, Joan
    Bermejo, Begona
    Lluch, Ana
    Prat, Aleix
    Arribas, Joaquin
    Eroles, Pilar
    Miguel Cejalvo, Juan
    SCIENCE ADVANCES, 2022, 8 (20):
  • [27] Issues and controversies in the treatment of HER2 positive metastatic breast cancer
    Surabhi Amar
    Alvaro Moreno-Aspitia
    Edith A. Perez
    Breast Cancer Research and Treatment, 2008, 109 : 1 - 7
  • [28] Targeting HER2 for the Treatment of Breast Cancer
    Rimawi, Mothaffar F.
    Schiff, Rachel
    Osborne, C. Kent
    ANNUAL REVIEW OF MEDICINE, VOL 66, 2015, 66 : 111 - 128
  • [29] Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
    Advani, Pooja
    Cornell, Lauren
    Chumsri, Saranya
    Moreno-Aspitia, Alvaro
    BREAST CANCER-TARGETS AND THERAPY, 2015, 7 : 321 - 335
  • [30] Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer
    Czink, E.
    Heining, C.
    Weber, T. F.
    Lasitschka, F.
    Schemmer, P.
    Schirmacher, P.
    Weiss, K. H.
    Glimm, H.
    Brors, B.
    Weichert, W.
    Jaeger, D.
    Froehling, S.
    Springfeld, C.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2016, 54 (05): : 426 - 430
12345